)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Sartorius Stedim Biotech (DIM) investor relations material
Sartorius Stedim Biotech Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary16 Oct, 2025
Executive summary
Sales grew by 7.5% in constant currencies to €2.6 billion for the nine-month period, driven by strong recurring consumables demand and margin expansion to 29.7%, despite FX headwinds.
Bioprocess Solutions (BPS) delivered double-digit growth in recurring business, offsetting softness in equipment, while Lab Products and Services (LPS) showed gradual improvement and stabilization.
All regions contributed to growth, with the Americas and Asia-Pacific leading, and China stabilizing.
Underlying net profit and EPS saw significant increases, with net profit after non-controlling interest up 68.5%.
Management raised full-year guidance, expecting around 9% sales growth and a 31% underlying EBITDA margin.
Financial highlights
Underlying EBITDA grew 12.8% to €774 million, with margin up 200 bps to 29.7%.
Underlying EPS increased by 17% year-over-year; reported net profit up 66% to €125 million.
Operating cash flow was €511 million, and free cash flow reached €200 million, both lower due to working capital and capex.
Capital expenditures totaled €276 million, representing 12.6% of sales revenue.
Gross profit for the nine months was €1,028.4 million, up from €890.4 million year-over-year.
Outlook and guidance
Full-year 2025 group sales growth expected at around 7% in constant currencies; BPS at 9%, LPS roughly flat.
Underlying EBITDA margin forecast slightly above 29.5% for the group, above 31.5% for BPS, and around 21.5% for LPS.
CapEx ratio expected at 12.5–13% of sales; net debt/EBITDA to decrease to approximately 3.5x by year-end.
For Sartorius Stedim Biotech, sales growth guidance upgraded to 9% in constant currencies, with EBITDA margin at 31%.
Management raised full-year guidance to the upper end of the forecast range.
What is the outlook for bioprocess equipment demand?
Reconcile strong profit growth with lower free cash flow.
What factors underpin the sharpened 2025 guidance?
Bioprocessing market growth outlook?
China bioprocessing market share shifts?
Update on Long-Range Plan timing?
2026 BPS growth: capital equipment needed?
China market share: customers returning to Western?
LPS margin resilience ex-volume?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sartorius Stedim Biotech earnings date
Q4 202527 Jan, 2026
Next Sartorius Stedim Biotech earnings date
Q4 202527 Jan, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sartorius Stedim Biotech S.A. is a global supplier of biopharmaceutical equipment and services, specializing in the development of products used in the manufacture of vaccines, biologics, and cell-based therapies. The company offers a wide range of solutions, including bioreactors, filtration systems, and single-use technologies, aimed at optimizing and accelerating biopharmaceutical production processes. The company is headquartered in Aubagne, France, and its shares are listed on Euronext Paris.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage